Brief: Oncopeptides Abandons Type II Variation Process For Pepaxti
28/09/2023 11:13
Sept 28 (Reuters) - Oncopeptides AB ONCO.ST :
* OPTS TO ABANDON TYPE II VARIATION PROCESS FOR PEPAXTI TO
OPTIMIZE PATIENT AND SHAREHOLDER VALUE
Source text for Eikon: ID:nMFNbJfPRn
Further company coverage: ONCO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Oncopeptides AB
See all newsSweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study
Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy